BOARD OF DIRECTORS
Luc Dochez
Droia Ventures
Luc has been a Managing Partner at Droia Ventures since early 2020, a VC firm focused on genetic diseases and oncology with currently over €600 million under management. He currently serves as Droia’s representative on the Boards of Montis Biosciences (Chairman), Vaderis, Volastra, Muna, Quralis, Vico Therapeutics (Chairman), and Alesta (Chairman).
Dan Estes
Frazier Life Sciences
Dan is a General Partner on the Frazier Life Sciences team and has been involved with investing in and building many of Frazier’s biopharmaceutical portfolio companies over the past 14 years. Dan has been a co-founder and board member of Lengo Therapeutics (acquired by Blueprint Medicines), Arcutis (NASDAQ: ARQT), Sudo Bio, Inipharm, and Iolyx Therapeutics, and is a founding investor and board member at Radionetics Oncology, Eyconis, and Callio Therapeutics.
Laura Brass PhD, MBA
Novartis Venture
Laura Brass, PhD, MBA, is a Managing Director at the Novartis Venture Fund in Cambridge, MA, USA. Prior to NVF, Laura was a Managing Director at MPM Capital and, before that, a member of the founding management team and SVP BD for TriNetX. Laura has held various roles in business development and IP strategy, and was CEO of Aferon, an early-stage antiviral start-up.
Droia Ventures
Janwillem Naesens
Janwillem Naesens is the Managing Partner of Droia Ventures, a specialist life science investor focusing on early-stage biotech companies developing therapeutics for oncology and genetic disease.
​​Janwillem serves on the board of Frontier Medicines, Ambagon, Highlight Therapeutics, and Alesta Therapeutics. Janwillem holds an MSc in Engineering from the University of Leuven and an MBA from INSEAD, Fontainebleau.
Ilan Ganot
Alesta Therapeutics
Ilan Ganot is the Chief Executive Officer and a member of the Board of Directors at Alesta Therapeutics, a biotechnology company dedicated to the development of innovative small-molecule therapies for rare diseases. Mr. Ganot is the co-founder of Solid Biosciences and has served as a member of Solid’s Board of Directors since the Company’s inception in 2013. He also served as Solid’s Chief Executive Officer from 2013 to December 2022 and as Solid’s President from June 2018 to December 2022. Mr. Ganot is also a member of the Board of Directors of Minovia Therapeutics, a mitochondria biotechnology company.